Ohm20
Your research and information is invaluable to
Ohm20
Your research and information is invaluable to this community. Thank you!
I have a question for you or others here...
With this huge list, what is the process and potential for trials. I understand that doctors can proscribe off label once approved, but will cytodyn run trials on all these in your opinion. Once revenue starts i would assume there would be enough cash flow to fund and organize numerous trials as well as staff up the corporate office to organize and support. I would assume they would target the largest need or cash flow potential.
What do you see as potential research and uses. I would imagine that without a trial and listing a patient would have to put up a pretty big fight to get LL for their diagnosis when it isnt FDA approved for the application. I would assume it would be the rare doctor to venture off standard protocol.
I ask because i have two family members that have been diagnosed with Alzheimers and Lewy Dementia (which is not on your list and my brief research is not good enough to tunnel down to what makes it tick. Seems to be deposits in brain cells disrupting normal action, but i cant figure out what makes the deposits occur and maybe the researchers dont know either)
Needless to say, I doubt either could be a candidate for LL at this stage of developement and approval. I dont think the Alzheimers study has really started in NY either. Lewy i doubt is on anyones radar.
So given that it seems to me that usage for Alzheimers and most of your other indications is realistically a few years off. I would assume that trials would take at least a year or more per indication depending on the type of disease as well as time for FDA to grant approval.
Am I off base or pretty close to your thoughts?
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Holiday Cheer Abounds in Orlando Orlando's never a letdown when it comes to spectacle, but this holiday season, they've taken it up a notch and a half. The city's bursting with festivities, from the iconic theme parks to lively local events that offer something for everyone. Whether you're entertaining kids or looking for grown-up glitz, Orlando's got you sorted. Merry...
Continue Reading
Rethinking 3D Content Creation Well, well, well, Tripo AI is shaking things up in the 3D world with its new Agentic Canvas. This isn't just another gizmo to throw in the digital drawer; it's a tool looking to flip the whole 3D game on its head. Picture taking complex 3D workflows and molding them like clay into something that’s efficient and scalable. That’s what...
Continue Reading
Innovation Meets Collaboration at HikTech Star Tour Ever been to one of those tech expos that's more about hype than substance? No smoke and mirrors here. The 2026 HikTech Star Tour wasn’t your run-of-the-mill tech meet-up. Held in Hangzhou, the event brought together 130 tech professionals from 56 countries. It’s like a digital United Nations, but with fewer speeches...
Continue Reading
Riding the Edible Oil Wave The edible oils market seems to be gearing up for a steady rise. Folks, the numbers are speaking loud and clear. We're looking at the market booming from USD 277.74 billion in 2026 to a hefty USD 351.08 billion in 2031. According to MarketsandMarkets™, a compound annual growth rate (CAGR) of 4.8% is on the cards. Now, if that doesn't get the...
Continue Reading
Scrutinizing Pampa Energía’s Performance in Q3 2026 Pampa Energía, that Argentinian energy powerhouse, is strutting its stuff with the latest financial results. But let's not jump on the bandwagon just yet. The numbers are a kaleidoscope, promising at first blush with a pang of caution underneath. Sales for Q3 2026 hit a robust US$790 million, a triumphant 34%...
Continue Reading
Singapore's Bold Step into Precision Medicine When it comes to revolutionizing healthcare, Singapore isn't content to sit on the sidelines. They've just thrown a serious hat into the ring with the SG-INSIGHT study, a cornerstone of their National Precision Medicine programme. And Illumina, Inc. (NASDAQ:ILMN) is right there in it, gearing up to sequence the genomes of...
Continue Reading
MOBILion Joins Waters' Fold: A New Era for Proteomics Ah, the biotech world just saw another big whirl with Waters Corporation snagging MOBILion Systems. Now, this isn't just some stroll in the market park. We're talking about weaving MOBILion's fancy high-resolution ion mobility separation tech right into Waters' already robust mass spectrometry setup. These folks are...
Continue Reading
New Crosshairs on Coastal Financial Corporation Man, it's another day and yet another fiasco in the corporate world. Late-breaking news from the trenches alerts us that Coastal Financial Corporation is in the legal spotlight. Yeah, you heard me right. We're talking about NASDAQ:CCB, the darlings turned defendants courtesy of recent allegations that could rock their stock....
Continue Reading
Midterms Mingle with Financial Markets Folks, throw those ballots into the ring, because today the midterms are kicking things off and boy, are they shaking up the game on these prediction markets. Traders and exchanges are on their toes, and the money's flowing like cold brew in July. Robinhood, Intercontinental Exchange, CME Group, and others reported noticeable ripples...
Continue Reading
Nordic Semiconductor's Cutting-Edge Leap Let's cut through the noise: Nordic Semiconductor's latest move in the wireless landscape is a big deal, especially if you're the sort counting beans down to the last cent. Their fresh-off-the-press nRF71 Series of Systems-On-Chip (SoCs) pulls off a neat trick: it delivers Wi-Fi, Bluetooth LE, Thread, and edge AI on one chip, and...
Continue Reading
Top 5 Most Recently Viewed Articles
BOXX Insurance Embraces Growth in the U.S. Market BOXX Insurance is strategically enhancing its footprint in the U.S. market by appointing key leadership positions aimed at innovation within the cyber insurance space. This forward-thinking global insurtech is committed to delivering unique solutions tailored for both businesses and consumers. The expansion signifies a...
Continue Reading
Celleste Bio™ Achieves Landmark Cocoa Butter Production Celleste Bio™, an innovative cocoa technology company, has proudly announced a groundbreaking milestone in transforming the cocoa supply chain. The firm has unveiled its first-ever chocolate grade cocoa butter produced using cutting-edge plant cell culture technology, making waves in the agro-technological...
Continue Reading
Understanding VINCI's Share Capital and Voting Rights Total VINCI, a prominent French public limited company, is recognized for its significant role in infrastructure and construction. With a robust share capital totaling €1,474,737,915.00, the company's extensive operational framework has positioned it as a leader in its sector. Share Structure Overview As of the...
Continue Reading
Rezolve Ai's Daniel Wagner Advocates for UK AI Advancement In a significant announcement, Daniel Wagner, CEO and founder of Rezolve Ai (NASDAQ: RZLV), expressed strong support for the UK government's initiative to establish a National Data Library. This decision aims to enhance access to high-quality data for developers, a move Wagner characterizes as a pivotal moment for...
Continue Reading
Future Innovations in Art and Technology The China (Hangzhou) Art and Technology Biennale recently launched at the Yuhang Art Museum, serving as a significant platform for cultural exchange and artistic expression. This remarkable event, organized by the China Academy of Art (CAA) along with various art institutions and governmental bodies, showcases a diverse range of...
Continue Reading